Skip to main content

Advertisement

Table 1 Patient characteristics

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Characteristics Cases (n = 19)
Patient age, median (range), years 33 (3–57)
Sex
 Male 13
 Female 6
Diagnosis
 AML 3
 ALL 7
 MDS 7
 PID 2
Pre-HSCT EBV status, donor/recipient
 Positive/positive 19
MNC, median (range), × 108/kg 5.17 (2.53–9.59)
CD34+ cell absolute count, median(range), ×106/kg 6.37 (1.61–11.13)
CD3+ cell absolute count, median(range), ×108/kg 2.76 (0.82–7.83)
Engraftment
 White cells, median (range), days 12 (10–18)
 Platelets, median (range), days 13 (9–18)
Acute graft-versus-host disease, n
 No 7
 I–II degree 10
 III–IV degree 2
EBV infection after HSCT within 100 days
 No 9
 EBV-DNAemia 5
 EBV disease 5
CSA stop
 No 4
 Yes 15
CSA stopping time, median (range), days 32.5 (4–88)